Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

Abstract
We analysed the clinical features, distribution of basal markers, prevalence of oncogene amplification, and outcome of triple negative (TN) compared to those of non-TN cancers in a series of adjuvant-anthracycline treated breast cancer patients.